Department of Respiratory & Immunology Toxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
ApconiX, Macclesfield, UK.
Int J Toxicol. 2024 Jan-Feb;43(1):4-18. doi: 10.1177/10915818231206025. Epub 2023 Oct 20.
HFO-1234ze (E) is proposed as a near zero global warming propellant for use in metered dose inhaled (MDI) products. This paper describes the non-clinical safety assessment in mice, rats, and dogs and supplements previously reported data (genetic toxicology, short-term toxicology, and reproductive toxicology). In all species, HFO-1234ze (E) was only detectable in blood for a short period after dosing with no evidence of accumulation. HFO-1234ze (E) was without any toxicological effects at very high doses in subchronic (13-week mouse) and chronic (39-week dog) studies. Chronic (26-week) administration to rats at very high doses was associated with an exacerbation of rodent progressive cardiomyopathy, a well-documented background finding in rodents. In a 2-generation study, extremely high doses were associated with the early euthanasia of some lactating female rats. This finding was considered to be significantly influenced by a state of negative energy balance, reflecting the specific vulnerability of rats during lactation. These findings are considered to not pose a risk to humans with typical MDI use given they occurred at doses which far exceed those expected in patients. Overall, the nonclinical safety data for HFO-1234ze (E) support its further development as an MDI propellant.
HFO-1234ze(E) 被提议作为一种用于计量吸入器(MDI)产品的近零全球变暖推进剂。本文描述了在小鼠、大鼠和狗中的非临床安全性评估,并补充了先前报告的数据(遗传毒性、短期毒性和生殖毒性)。在所有物种中,HFO-1234ze(E) 在给药后仅在短时间内可在血液中检测到,没有蓄积的证据。在亚慢性(13 周小鼠)和慢性(39 周狗)研究中,HFO-1234ze(E) 在非常高的剂量下没有任何毒理学效应。在非常高的剂量下,慢性(26 周)给予大鼠与啮齿动物进行性心肌病的加剧有关,这是啮齿动物中一种记录良好的背景发现。在两代研究中,一些哺乳期雌性大鼠因极高剂量而提前安乐死。这一发现被认为受到负能平衡状态的显著影响,反映了哺乳期大鼠的特定脆弱性。这些发现被认为不会对典型 MDI 使用的人类构成风险,因为它们发生在远远超过患者预期的剂量下。总体而言,HFO-1234ze(E) 的非临床安全性数据支持其进一步开发为 MDI 推进剂。